Anti-CDKN1A/p21CIP1 Rabbit Monoclonal Antibody for WB, IHC-P, ELISA - P38936

Core Product Specifications and Parameters

Biological Background: CDKN1A/p21CIP1 Function and Localization

• Cyclin-dependent kinase inhibitor 1, designated CDKN1A, is also known as p21, CIP1, WAF1, SDI1, CAP20, CDKN1, and MDA-6. It functions as a potent regulator of the cell cycle.
• CDKN1A plays a critical role in p53/TP53-mediated cell cycle arrest in response to DNA damage, blocking G1/S progression and enabling DNA repair (PubMed:9106657). Related references: PMID:9106657
• The protein binds to and inhibits cyclin-dependent kinase (CDK) complexes, preventing phosphorylation of key substrates such as RB1, thereby halting cell cycle progression.
• At low stoichiometric ratios, CDKN1A promotes the nuclear localization and assembly of the cyclin D-CDK4 complex, enhancing its kinase activity toward RB1, whereas at higher ratios it inhibits the complex.
• CDKN1A competes with POLD3 for binding to proliferating cell nuclear antigen (PCNA), resulting in inhibition of DNA synthesis by DNA polymerase delta (PubMed:11595739). Related references: PMID:11595739
• The protein primarily localizes to the nucleus but is also found in the cytoplasm. Its nuclear localization is essential for CDK inhibition, and its activity is modulated by post-translational modifications including phosphorylation, acetylation, and ubiquitination.
• CDKN1A is ubiquitously expressed in adult tissues, with approximately five-fold lower levels in the brain compared to other tissues.
• Besides its canonical role, CDKN1A participates in p53-independent DNA damage-induced G2 arrest via the CREB3L1 pathway in astrocytes and osteoblasts (By similarity).

Experimental Guidance and Technical Tips

• The immunogen comprises the N-terminal 164 amino acids of human CDKN1A/p21CIP1, covering the full-length protein; confirm that the antibody detects endogenous p21 at approximately 18 kDa by Western blot.
• For immunohistochemistry (IHC-P), both nuclear and cytoplasmic staining may be observed. Optimize antigen retrieval and antibody dilution using known positive control tissues such as colon carcinoma or proliferating cells.
• In ELISA applications, use recombinant p21 protein or cell lysates from p53-activated samples to establish standard curves and validate specificity.
• Since p21 expression is tightly regulated by p53 and cellular stress, consider treating cells with DNA-damaging agents (e.g., doxorubicin) to induce p21 prior to detection.

CamelBio: Your One-Stop Sourcing Bridge

As your dedicated one-stop sourcing bridge, CamelBio provides diagnostic manufacturers and research laboratories with reliable access to high-quality IVD raw materials. This anti-CDKN1A/p21CIP1 monoclonal antibody supports cell cycle and oncology research, and fits seamlessly into CamelBio’s comprehensive portfolio—including validated antibody pairs, optimized monoclonals and polyclonals, bulk ancillary reagents, and custom rare target sourcing. Let us streamline your procurement from concept to clinic.